News

/
/
WP4 PTJA01 on “Midostaurin (Rydapt©) with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia” is now available.

WP4 PTJA01 on “Midostaurin (Rydapt©) with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia” is now available.

Final assessment report on Midostaurin (Rydapt©)

We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Midostaurin (Rydapt©) with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia” is now available. The final assessment report was published in November 2017. Find the documentation provided by the authoring team here.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.